Abstract:The histone acetyltransferases CBP and p300, often referred to as CBP/p300 due to their sequence homology and functional overlap and co-operation, are emerging as critical drivers of oncogenesis in the past several years. CBP/p300 induces histone H3 lysine 27 acetylation (H3K27ac) at target gene promoters, enhancers and super-enhancers, thereby activating gene transcription. While earlier studies indicate that CBP/p300 deletion/loss can promote tumorigenesis, CBP/p300 have more recently been shown to be over-expressed in cancer cells and drug-resistant cancer cells, activate oncogene transcription and induce cancer cell proliferation, survival, tumorigenesis, metastasis, immune evasion and drug-resistance. Small molecule CBP/p300 histone acetyltransferase inhibitors, bromodomain inhibitors, CBP/p300 and BET bromodomain dual inhibitors and p300 protein degraders have recently been discovered. The CBP/p300 inhibitors and degraders reduce H3K27ac, down-regulate oncogene transcription, induce cancer cell growth inhibition and cell death, activate immune response, overcome drug resistance and suppress tumor progression <i>in vivo</i>. In addition, CBP/p300 inhibitors enhance the anticancer efficacy of chemotherapy, radiotherapy and epigenetic anticancer agents, including BET bromodomain inhibitors; and the combination therapies exert substantial anticancer effects in mouse models of human cancers including drug-resistant cancers. Currently, two CBP/p300 inhibitors are under clinical evaluation in patients with advanced and drug-resistant solid tumors or hematological malignancies. In summary, CBP/p300 have recently been identified as critical tumorigenic drivers, and CBP/p300 inhibitors and protein degraders are emerging as promising novel anticancer agents for clinical translation.

Discovery of Highly Potent, Selective, and Orally Efficacious P300/cbp Histone Acetyltransferases Inhibitors

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors

Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy

CBP/p300 bromodomain: new promising epigenetic target

Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.

Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment

Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma

Discovery of Novel Benzimidazole Derivatives As Potent P300 Bromodomain Inhibitors with Anti-Proliferative Activity in Multiple Cancer Cells.

Current development of CBP/p300 inhibitors in the last decade

Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders

Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins

Discovery of Novel CBP Bromodomain Inhibitors Through TR-FRET-based High-Throughput Screening

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

Recent Advances In The Discovery Of Hif-1 Alpha-P300/Cbp Inhibitors As Anti-Cancer Agents

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

Design, Synthesis and Biological Evaluation of a Novel Spiro Oxazolidinedione As Potent P300/cbp HAT Inhibitor for the Treatment of Ovarian Cancer.